The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2023-01-01
-Paragraph 38
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_38&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 85
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_OtherOperatingIncomeExpense
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Anti programmed cell death protein 1 sales milestone payment.

+ References

No definition available.

+ Details

Name:	sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contractual Agreement For Anti-programmed Cell Death Protein1

+ References

No definition available.

+ Details

Name:	sny_ContractualAgreementForAntiProgrammedCellDeathProtein1
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Disclosure of Principal Alliances [Line Items]

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfPrincipalAlliancesLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum additional funding for anti programmed cell death protein 1 part of each company.

+ References

No definition available.

+ Details

Name:	sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum sales of anti programmed cell death protein 1 in twelve month period to be achieved for milestone payment.

+ References

No definition available.

+ Details

Name:	sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number Of Agreements Signed

+ References

No definition available.

+ Details

Name:	sny_NumberOfAgreementsSigned
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of cumulative development costs reimbursed.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of profit share on counter parties profit.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Prior development budget.

+ References

No definition available.

+ Details

Name:	sny_PriorDevelopmentBudget
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Proceeds From Collaboration Agreements

+ References

No definition available.

+ Details

Name:	sny_ProceedsFromCollaborationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Regular Milestone Payments For Projects Under Collaboration Agreements

+ References

No definition available.

+ Details

Name:	sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty Income, Percentage

+ References

No definition available.

+ Details

Name:	sny_RoyaltyIncomePercentage
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Payments For Projects Under Collaboration Agreements

+ References

No definition available.

+ Details

Name:	sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_TypesOfAgreementAxis=sny_DevelopmentOfCemiplimabREGN2810Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details) € in Millions, $ in Millions			1 Months Ended				12 Months Ended
	Sep. 30, 2021 USD ($)	Jul. 01, 2015 agreement	Nov. 30, 2022 EUR (€)	Nov. 30, 2022 USD ($)	Jul. 31, 2022 EUR (€)	Jul. 31, 2022 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2015 USD ($)
Disclosure of Principal Alliances [Line Items]
Other operating income/(expenses), net related to Regeneron \| €							€ (2,979)	€ (1,231)		€ (1,373)
Assets held for sale or exchange \| €							15	85		€ 89
Regeneron Pharmaceuticals, INC
Disclosure of Principal Alliances [Line Items]
Assets held for sale or exchange \| €								226
Regeneron Pharmaceuticals, INC \| Immuno-oncology collaboration agreement
Disclosure of Principal Alliances [Line Items]
Number of agreements signed \| agreement		2
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)											10.00%
Percentage of cumulative development costs reimbursed											50.00%
Upfront payments for projects under collaboration agreements \| $									$ 900
Regular milestone payments for projects under collaboration agreements			€ 96	$ 100					$ 100
Regeneron Pharmaceuticals, INC \| Immuno-oncology collaboration agreement \| Major Collaboration Agreement
Disclosure of Principal Alliances [Line Items]
Upfront payments for projects under collaboration agreements					€ 856	$ 900
Royalty income percentage (percentage)					11.00%	11.00%
Other operating income/(expenses), net related to Regeneron \| €							116	111
Proceeds from collaboration agreements \| €							€ 196	€ 952
Regeneron Pharmaceuticals, INC \| Immuno-oncology collaboration agreement \| Development of cemiplimab (REGN2810)
Disclosure of Principal Alliances [Line Items]
Prior development budget in total \| $											$ 1,640
Contractual agreement for anti-programmed cell death protein											5000.00%
Maximum additional funding for PD1 - part of each company \| $	$ 1,840										$ 820
PD1 sales milestone payment from Sanofi \| $											375
Minimum sales of PD1 in 12-month period to be achieved for milestone payment \| $											$ 2,000